Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fluoride-free cavity fighter?

This article was originally published in The Tan Sheet

Executive Summary

Ortek Therapeutics has "begun its formal pursuit" of new drug applications for two new Rx products containing CaviStat, a cavity-fighting complex that mimics saliva's anti-cavity properties, the firm says July 11. Cavistat contains arginine, the common amino acid that neutralizes erosive acids while strengthening and repairing the tooth structure with calcium carbonate and bicarbonate, the firm states. Ortek hopes to have DenClude Desensitizing Dental Cream approved as the first flouride-free cavity fighting toothpaste in the world. The product already is an Rx toothpaste indicated for the management of tooth sensitivity. The firm also is pursuing approval of BasicMints as the first cavity-fighting confection available to consumers worldwide. While fluoride helps to remineralize teeth, it can have toxic side effects and lead to bone fractures after prolonged use, Ortek maintains. The firm says it will eventually pursue OTC status for the products...

You may also be interested in...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts